神経バイオマーカーの市場規模、シェア、成長分析、タイプ別、用途別、エンドユーザー別、地域別 - 産業予測、2024年～2031年

神経バイオマーカー市場規模は2022年に61億3,000万米ドルと評価され、予測期間（2024-2031年）のCAGRは13.6%で、2023年の69億6,000万米ドルから2031年には193億1,000万米ドルに成長する見通しです。

世界の神経バイオマーカー市場は、主にアルツハイマー病、パーキンソン病、多発性硬化症などの神経疾患の有病率の上昇と、精密な診断ツールに対する需要の増加を背景に、大きく拡大する見通しです。世界の高齢化とライフスタイルの変化により、これらの疾患が急増し、早期介入と疾患管理の強化を可能にする効果的な診断の必要性が高まっています。精密医療や標的治療へのシフトは、ヘルスケアプロバイダーが個人の遺伝的・分子的プロファイルに基づいて治療を調整し、副作用を最小限に抑えながら転帰を最適化することを可能にする神経バイオマーカーへの需要をさらに加速させています。しかし、神経疾患の複雑な性質に起因する課題に直面しており、信頼性の高いバイオマーカーの同定と検証を複雑にしています。バイオマーカーの感度、特異性、予測値を決定するためには広範な調査と臨床試験が必要であり、多くの場合、時間とコストのかかるプロセスにつながります。さらに、患者のプライバシーの確保やインフォームド・コンセントなど、バイオマーカー開発に関連する規制や倫理の課題については、研究者と医療従事者の双方が慎重に検討する必要があります。バイオマーカーアッセイとデータ解釈における標準化の欠如は、研究室技術の不一致が研究間の比較可能性を妨げる可能性があるため、もう一つのハードルとなります。とはいえ、米国の神経バイオマーカー市場は堅調な軌道を描いており、今後の予測期間においても持続的な成長と有望な機会が期待されます。

目次

イントロダクション

• 調査の目的
• 定義
• 市場範囲

調査手法

• 情報調達
• 二次データソースと一次データソース
• 市場規模予測
• 市場の想定と制限

エグゼクティブサマリー

• 市場概要見通し
• 供給需要動向分析
• セグメント別機会分析

市場力学と見通し

• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題
• ポーターの分析

主な市場の考察

• 主な成功要因
• 競合の程度
• 主な投資機会
• 市場のエコシステム
• 技術分析
• パイプライン分析
• 浸透と成長の見通し分析
• PESTEL分析
• 特許分析

神経バイオマーカー市場：タイプ別

• 市場概要
• ゲノム
• プロテオーム
• メタボロミクス
• イメージング
• その他

神経バイオマーカー市場：用途別

• 市場概要
• アルツハイマー病
• パーキンソン病
• 多発性硬化症
• 自閉症スペクトラム障害
• その他

神経バイオマーカー市場：エンドユーザー別

• 市場概要
• 病院および病院検査室
• 独立臨床診断センター
• 研究機関等

神経バイオマーカー市場規模：地域別

• 市場概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ（MEA）
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ地域

競合情勢

• 上位5社の比較
• 主要企業の市場ポジショニング（2023年）
• 主な市場企業が採用した戦略
• 市場における最近の活動
• 主要企業の市場シェア（2023年）

主要企業プロファイル

• Quanterix Corporation
• Thermo Fisher Scientific Inc.
• Myriad Genetics, Inc.
• QIAGEN N.V.
• Bio-Rad Laboratories, Inc.
• Merck KGaA
• F. Hoffmann-La Roche Ltd
• Bio-Techne Corporation
• Alector Inc.
• bioMerieux
• Charles River Laboratories International, Inc.
• Cisbio
• C2N Diagnostics
• ImmunArray
• Euroimmun AG
• Abbott Laboratories

Neurological Biomarkers Market size was valued at USD 6.13 Billion in 2022 and is poised to grow from USD 6.96 Billion in 2023 to USD 19.31 Billion by 2031, at a CAGR of 13.6% during the forecast period (2024-2031).

The global neurological biomarkers market is poised for significant expansion, driven primarily by the rising prevalence of neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis, alongside an increasing demand for precise diagnostic tools. The aging global population and lifestyle factors have resulted in a surge of these conditions, fueling the need for effective diagnostics that enable early intervention and enhanced disease management. The shift towards precision medicine and targeted therapies further accelerates the demand for neurological biomarkers, which allow healthcare providers to tailor treatments based on individual genetic and molecular profiles, thereby optimizing outcomes while minimizing adverse effects. However, the market confronts challenges stemming from the intricate nature of neurological diseases, which complicates the identification and validation of reliable biomarkers. Extensive research and clinical trials are necessary to determine the sensitivity, specificity, and predictive value of biomarkers, often leading to time-consuming and costly processes. Additionally, regulatory and ethical challenges related to biomarker development, such as ensuring patient privacy and informed consent, need careful consideration from both researchers and healthcare professionals. The lack of standardization in biomarker assays and data interpretation presents another hurdle, as inconsistencies in laboratory techniques can hinder comparability across studies. Nevertheless, with a robust market trajectory, the US neurological biomarkers sector is expected to witness sustainable growth and promising opportunities in the forthcoming forecast period.

Top-down and bottom-up approaches were used to estimate and validate the size of the Neurological Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Neurological Biomarkers Market Segmental Analysis

Global Neurological Biomarkers Market is segmented by Type, Application, End User and Region. Based on Type, the market is segmented into Genomic, Proteomic, Metabolomic, Imaging, Others. Based on Application, the market is segmented into Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder, Others. Based on End User, the market is segmented into Hospital & Hospital Laboratories, Independent Clinical Diagnostic Centers, Research Organizations and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa

Driver of the Neurological Biomarkers Market

The rising prevalence of neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis, serves as a critical market driver for the global neurological biomarkers market. With the aging population and lifestyle factors contributing to the surge in these conditions, there is an escalating demand for accurate, early diagnostic tools that can facilitate timely intervention and improve patient outcomes. Neurological biomarkers play a vital role in enhancing disease detection, monitoring progression, and evaluating treatment efficacy. As healthcare providers and researchers increasingly recognize the importance of personalized medicine, the need for innovative biomarkers to support tailored therapeutic approaches further propels market growth in this sector.

Restraints in the Neurological Biomarkers Market

One of the significant market restraints for the neurological biomarkers industry is the extensive and resource-intensive process required for their discovery and validation. This involves conducting comprehensive research and lengthy clinical trials that not only demand substantial financial investment but also extended timelines, which can impede the speed of bringing these innovations to market. Consequently, the high costs associated with the development and validation of biomarkers can limit access to these advanced diagnostic and therapeutic options, making them less affordable for healthcare providers and patients alike. This financial barrier may hinder the widespread adoption of neurological biomarkers in clinical practice, ultimately affecting market growth.

Market Trends of the Neurological Biomarkers Market

The Neurological Biomarkers market is witnessing a significant trend towards the integration of Artificial Intelligence (AI) and Machine Learning (ML) technologies, which are revolutionizing biomarker research and data analysis. This shift enables the automation of data interpretation, thereby streamlining the identification of critical patterns and facilitating accurate predictions of disease outcomes. As a result, the efficiency and precision in the discovery and validation of neurological biomarkers are markedly improved. The increasing adoption of AI and ML not only accelerates research timelines but also enhances the overall reliability of diagnostics, reflecting a transformative movement that is poised to redefine approaches to neurological disorders.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Technology Analysis
• Pipeline Analysis
• Penetration and Growth Prospects Analysis
• PESTEL Analysis
• Patent Analysis

Neurological Biomarkers Market, By Type

• Market Overview
• Genomic
• Proteomic
• Metabolomic
• Imaging
• Others

Neurological Biomarkers Market, By Application

• Market Overview
• Alzheimer's Disease
• Parkinson's Disease
• Multiple Sclerosis
• Autism Spectrum Disorder
• Others

Neurological Biomarkers Market, By End User

• Market Overview
• Hospital & Hospital Laboratories
• Independent clinical diagnostic centers
• Research Organizations and Others

Neurological Biomarkers Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Quanterix Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Techne Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alector Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories International, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cisbio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• C2N Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ImmunArray
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Euroimmun AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments